Form 4: Sutro Biopharma Director Heidi Hunter Granted 50,000 Stock Options

Sutro Biopharma, Inc. Director Heidi Hunter was granted 50,000 stock options with an exercise price of $0.85, vesting monthly and fully by June 2026.

Summary

• Heidi Hunter, a Director of Sutro Biopharma, Inc. (STRO), reported the acquisition of 50,000 derivative securities in the form of stock options.
• The transaction date for this grant was June 6, 2025.
• Each option has an exercise price of $0.85 and represents the right to buy one share of Sutro Biopharma Common Stock.
• The options begin vesting at a rate of 8.33% of the total shares monthly, commencing July 6, 2025.
• Full vesting (100% of total shares) will occur on the earlier of the issuer's 2026 annual stockholders meeting or June 6, 2026, contingent on Ms. Hunter's continued service.
• The expiration date for these stock options is June 6, 2035.
• Following this reported transaction, Ms. Hunter beneficially owns 50,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a Form 4 is primarily a disclosure of an insider transaction, the grant of options to a director is a standard practice that aligns their interests with shareholders, which is generally viewed favorably for corporate governance and long-term strategy.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The vesting schedule of the granted stock options indicates an expectation of continued service from Director Heidi Hunter through at least June 2026, aligning her incentives with the company's long-term performance.

Industry Context

The granting of stock options is a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to attract and retain talent while aligning their financial interests with shareholder value creation. This practice is standard across publicly traded companies, particularly in growth-oriented sectors like biotech where long-term value appreciation is a key driver.

Comparison to Industry Standards

• The use of stock options as a compensation tool for directors is a standard practice across the biotechnology and broader public company landscape, comparable to compensation structures seen at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals, which frequently utilize equity grants to incentivize leadership.
• The vesting schedule, with monthly increments and a full vesting milestone tied to an annual meeting or a specific date, is typical for such grants, ensuring continued commitment over a defined period.

Corporate Governance

Related Party Transactions

• The grant of 50,000 stock options to Heidi Hunter, a Director of Sutro Biopharma, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's financial interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: While not directly impacting all employees, such compensation practices for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• Continued monthly vesting of the 50,000 stock options for Heidi Hunter, subject to her provision of service to Sutro Biopharma, Inc.

Key Dates

Keywords

Sutro Biopharma, STRO, Form 4, Insider Transaction, Stock Option, Director Compensation, Equity Grant, Beneficial Ownership